Dopachrome tautomerase (DCT) is a melanosomal enzyme that catalyzes the conversion of L-dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA), a critical step in eumelanin biosynthesis 1. This enzymatic activity positions DCT centrally in melanin formation from tyrosine precursors, enabling pigment-dependent photoprotection in melanocytic cells. Beyond pigmentation, DCT functions as a cellular stress-response protein. DCT depletion in melanoma cells and melanoblasts reduces survival following ultraviolet radiation (UVR) exposure and diminishes UVR-induced p53 phosphorylation 1. Conversely, DCT overexpression enhances melanocyte viability post-UVR, suggesting roles in DNA damage responses and oxidative stress resistance. These protective mechanisms are phenotype-dependent; melanoblasts carrying MC1R red hair color variants (RHC homozygotes) display variable p53 responses to DCT manipulation. Clinically, DCT dysfunction associates with oculocutaneous albinism type 8 (OCA8), an inherited disorder disrupting normal pigmentation. The enzyme's copper-dependent catalytic activity and melanosomal localization are essential for proper pigment development and skin photoprotection. Understanding DCT function elucidates both normal melanin biosynthesis and pathogenic mechanisms underlying hypopigmentary disorders, with implications for UV sensitivity and melanoma risk in affected individuals.